Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03159585 | To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors | PHASE1 | COMPLETED | 6 | — | — | Apr 14, 2017 | Jun 4, 2019 | Jan 22, 2020 | 1 | China |
The treatment-related adverse events of the patients received TAEST16001 treatment will be assessed by CTCAE v4.03
| Arm | Type | Description |
|---|---|---|
| TAEST16001 | EXPERIMENTAL | Patients who meet the inclusion criteria receive TAEST16001treatment after lymphodepleting by fludarabine and cyclophosphamide. |
| Name | Type | Description |
|---|---|---|
| TAEST16001 | DRUG | After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001 |
Inclusion Criteria: * sign an informed consent before undertaking any trial-related activities; * ≥18 and ≤75 years old; * Multi-line treatment failed Solid Tumors except non small cell lung cancer,including Liver Cancer,Gastric Cancer,Esophageal Cancer,Bone and Soft Tissue Tumors,Breast Cancer, Bl...